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ABSTRACT: A series of congeners structurally related to
pritelivir, N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-
methyl-2-[4-(2-pyridinyl)phenyl]acetamide, a helicase-primase
inhibitor for the treatment of herpes simplex virus infections,
was prepared. The synthesized primary and secondary
sulfonamides were investigated as inhibitors of six physiolog-
ically and pharmacologically relevant human (h) carbonic
anhydrase (hCA, EC 4.2.1.1) isoforms, the cytosolic enzymes
hCA I and II, the mitochondrial ones hCA VA and VB, and the
transmembrane, tumor associated hCA IX and XII. Low
nanomolar inhibition KI values were detected for all of them,
with a very interesting and well-defined structure−activity relationship. As many CAs are involved in serious pathologies, among
which are cancer, obesity, epilepsy, glaucoma, etc., sulfonamide inhibitors as those reported here may be of interest as drug
candidates. Furthermore, pritelivir itself is an effective inhibitor of some CAs, also inhibiting whole blood enzymes from several
mammalian species, which may be a favorable pharmacokinetic feature of the drug which can be transported throughout the body
bound to blood CA I and II.
■ INTRODUCTION
Pritelivir, (N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-
methyl-2-[4-(2-pyridinyl)phenyl]acetamide), previously
known as BAY 57-1293 and AIC316 (Figure 1),1 is an antiviral
agent in phase II clinical development, useful for the treatment
of herpes simplex virus (HSV) infections.1−3 Its mechanism of
action is totally different from that of other antiherpetic agents
such as acyclovir, penciclovir, and other nucleoside analogs
(which inhibit the herpesviral DNA polymerase after becoming
activated by the viral thymidine kinase), as pritelivir acts as a
helicase-primase inhibitor that does not need to become
activated.1−3 The phase I and II clinical trials were promising,
with the compound being well tolerated and effective showing
superiority over placebo and the nucleoside analog valacyclo-
vir.2,3
One of the interesting features of pritelivir is that the
compound incorporates a primary sulfonamide moiety not
present in any other antiviral agent. However, this functionality
is well-known for its affinity for the metalloenzyme carbonic
anhydrase (CA, EC 4.2.1.1),4−10 with many aromatic,
heterocylic, aliphatic, and sugar derivatives incorporating this
moiety, acting as highly effective CA inhibitors (CAIs).11−15 In
line with this, initial activity on carbonic anhydrase in the
micromolar range has been reported previously for pritelivir by
means of a carbonic anhydrase catalyzed CO2 hydration assay.
1
There are six genetic families encoding CAs in virtually all
organisms known to date, the α-, β-, γ-, δ-, ζ-, and η-CAs.6−9 All
CAs known so far are metal-ion-dependent enzymes, with a
metal hydroxide species within the enzyme cavity acting as a
nucleophile in the catalytic cycle and a second step (usually
rate-determining) involving a proton transfer reaction from a
water molecule coordinated to the active site metal ion to the
environment, for regenerating the nucleophile.4,7−10 Metal ions
employed at the active site of the different CAs include Zn(II)
(in all classes), Cd(II) (in ζ-CAs), Co(II) (in the δ class), or
Fe(II) (for γ-CAs, in anaerobic conditions).4 This ping-pong
mechanism makes some of the members of the CA superfamily
among the most effective enzymes known in nature, with kcat/
KM values close to the limit of the diffusion-controlled
processes.10,11
The CAs possess crucial physiologic functions, as the
reaction products obtained from the hydration of CO2 are
involved in pH regulation (bicarbonate and protons) but also in
many biosynthetic processes (lipogenesis, ureagenesis, gluco-
neogenesis) or in other important phenomena such as
chemosensing,4 sexual development (in pathogenic fungi),8
pH and CO2-sensing, pathogenicity, and survival in ambient air
of many bacteria, fungi, and/or protozoa.7−10
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In humans, 15 α-CAs isoforms are known to date, CA I to
CA VA, CA VB, CA VI to CA XIV, with 12 of them being
catalytically active and three (CA VIII, X and XI) devoid of
activity but still playing significant functions in tumorigenesis
and other physiologic as well as pathologic processes.4
As CO2, bicarbonate, and protons are simple molecules/ions
involved in a host of physiologic processes, some of which are
briefly mentioned above, their up- or down-regulation is
associated with a range of diseases.12−15 Indeed, the CAIs of the
primary sulfonamide type (but many other chemotypes were
reported, such as the coumarins,16 sulfocoumarins,17 mono-
and dithiocarbamates,18 etc.) are clinically used for decades as
diuretics,4,11 antiepileptics,12 antiobesity agents,13 antiglaucoma
drugs,4,15 or more recently antitumor agents, with one such
compound in clinical development for the treatment of
hypoxic, metastatic tumors.4,19 Although many new chemo-
types with CA inhibitory properties and with various
mechanisms of actions were reported in the past 10
years,16−18 the sulfonamides remain the most investigated
class of such compounds with many interesting representatives
being reported constantly.19,20
One of the main hurdles connected with the use of CAIs in
the treatment of diverse conditions as those mentioned above is
related to the off-target inhibition of isoforms other than the
desired one.4 In fact the various pharmacological applications of
the CAIs are due to the high number of isoforms and their
involvement in different pathologies.11−15
■ RESULTS AND DISCUSSION
Compound Design and Synthesis. Many sulfonamide
CAIs incorporate an elongated scaffold which contains a five-
membered heterocyclic ring on which the SO2NH2 zinc
binding group moiety and a tail are attached on the two
sides of the cycle in such a way that the tail extends as much as
possible within the enzyme active site and makes interactions
with amino acid residues at the entrance of the cavity, which are
the least conserved residues among the many mammalian
isoforms known.4−11,21 Most of the time the five-membered
heterocyclic ring was an 1,3,4-thiadiazole,21a,b a thiophene,21c
and rarely a thiazole nucleus.21d This type of scaffold leads to a
multitude of contacts between the inhibitor and the enzyme, as
shown schematically in Figure 2 for 5-[1-(naphthalen-1-yl)-1H-
1,2,3-triazol-4-yl]thiophene-2-sulfonamide bound to human (h)
isoform hCA II, as determined by X-ray crystallography.21c The
sulfamoyl zinc binding group (ZBG) is observed bound to the
catalytically crucial Zn(II) ion, whereas the organic scaffold of
the inhibitor is in contact with many amino acid residues
involved in inhibitor binding, such as Phe131, Val135, Leu204,
Pro202, extending throughout the cavity.21c
Such a binding for sulfonamide CAIs with elongated scaffolds
affords the possibility of obtaining compounds with very high
affinities for the enzyme (usually low nanomolar or
subnanomolar), and also many cases of isoform-selective
inhibitors were detected in this way.19−21 Considering that
pritelivir (Figure 1) also has this type of scaffold, with the
thiazole ring substituted with the sulfonamide ZBG and the (2-
pyridinyl)phenyl]acetamide fragment at positions 5 and 2,
respectively, we decided to first confirm the CA inhibitory
properties of this primary sulfonamide in our laboratory and
thereafter to use the molecule as a lead for obtaining new
sulfonamide CAIs.
In Schemes 1 and 2 the synthetic strategy to obtain a series
of thiazolyl-5-sulfonamides (including pritelivir) is shown.
2-Chlorothiazoles 1a,b were transformed to the correspond-
ing sulfonyl chlorides 2a,b. Reaction of 2a,b with ammonia or
primary amines led to sulfonamides 3a−e, which were
thereafter reacted again with amines in order to obtain the 2-
aminothiazole-5-sulfonamide derivatives 4a−h, incorporating a
series of different substituents at the 2-amino-, thiazole-4-
position and N-sulfonamide fragments of the molecule, in order
to generate chemical diversity (Scheme 1). Derivative 4a,
incorporating a 4-methyl moiety at the thiazole ring, was
converted into the corresponding 4-hydroxymethylene deriva-
tive 6 via monobromination with N-bromosuccinimide,
followed by displacement of the bromide 5 with water, thus
leading to the desired 2-aminomethyl-5-sulfonamidethiazole 6
incorporating the hydroxymethylene group at position 4
(Scheme 1).
In order to obtain the pritelivir-like compounds, the
intermediates 4a−h obtained as shown in Scheme 1 were
coupled with 4-substituted phenylacetic acids 7a−i in the
presence of carbodiimides leading to sulfonamides 8a−t
(derivative 8b is pritelivir). The chemical diversity was achieved
by varying the nature of the aromatic/heterocyclic moieties
which substitute the phenylacetic ring 7 at position 4, with
phenyl, 2-pyridyl, pyridinium, pyrazyl, pyrazoyl, and sub-
Figure 1. Chemical structures of the anti-HSV helicase-primase inhibitor pritelivir and herpesviral DNA polymerase inhibitors acyclovir and
penciclovir.
Figure 2. Binding of a thiophene-2-sulfonamide derivative to hCA II as
determined by X-ray crystallography (PDB file 4BF6).21c
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stituted-phenyl groups included in the study (Scheme 2).1b,23,24
The 4-ethyl (8s) and 4-hydroxymethyl (8t) analogs of pritelivir
(which has a 4-methyl for such moiety) were also prepared as
depicted in Scheme 2.
All compounds were properly characterized by spectroscopic
methods which confirmed their structure (1H NMR, 13C NMR,
MS, and IR). Purity was controlled by HPLC. All compounds
reported here were >98% pure.
Carbonic Anhydrase Inhibition. Sulfonamide reported
here were tested in vitro for their inhibition profiles against six
physiologically relevant hCA enzymes,25 the cytosolic isoforms
I and II, the mitochondrial ones hCA VA and VB, and the
transmembrane, tumor associated hCA IX and XII (Table 1).
The following structure−activity relationship (SAR) can be
drawn by considering data of Table 1. It should be stressed
from the beginning that most of these derivatives are primary
sulfonamides (8a−l, 8s, and 8t), four derivatives incorporate
the SO2NHMe moiety (8m−p), whereas 8q and 8r possess
bulkier substituents at the sulfamoyl nitrogen (see Scheme 2).
(I) The slow cytosolic isoform hCA I, widely present in the
blood, gastrointestinal tract, and many other tissues in
humans,4−11 was effectively inhibited by sulfonamides 8
investigated here, with KI values ranging between 26.6 and
543 nM (Table 1). Most of these sulfonamides were thus more
effective hCA I inhibitors compared to acetazolamide (AAZ, 5-
acetamido-1,3,4-thiadiazolesulfonamide), a clinically used drug
(KI of 250 nM).
4 The nature of the Het moiety present in the
final part of the tail seems to be the most important factor
influencing activity. For example, the phenyl-substituted
compound 8a is a 12 times more effective hCA I inhibitor
compared to pritelivir 8b which has a 2-pyridyl moiety instead
of the phenyl one. Thus, the replacement of one CH group by
an N atom leads to important changes in the inhibitory activity,
a phenomenon already documented by us for many classes of
CAIs by means of kinetic and X-ray crystallographic
studies.15−21 Compact R2 moieties (Me and cyclopropyl) led
to better hCA I inhibition in compounds incorporating them
(e.g., 8h−l) compared to the derivative incorporating a bulkier
such group (8g). There are no major differences of activity
between primary and secondary sulfonamides, and also the
nature of the group in position 4 of the thiazole (methyl, ethyl,
or hydroxyethyl) does not influence much the inhibitory power
of these sulfonamides (Table 1).
(II) The physiologically dominant isoform hCA II, widely
spread all over the body and a drug target for diuretic and
antiglaucoma agents,4,11,15 was also potently inhibited by most
sulfonamides 8 investigated here, with KI values ranging
between 0.9 and 341 nM (Table 1). Several compounds were
much more effective than AAZ as hCA II inhibitors (e.g., 8a, 8i,
8s, KI values ranging between 0.9 and 4.9 nM versus 12.1 nM
for AAZ), whereas pritelivir 8b and many of its congeners (8c,
8d, 8l, 8t) showed comparable (KI values of 10.0−32.9 nM) or
slightly weaker (8g, 8h, 8m, 8n, 8p, 8r) activity compared to
the standard drug (Table 1). SAR is rather similar to what was
stressed above for hCA I inhibition, with the nature of the Het
fragment of the molecule being the most important structural
feature influencing activity. Again phenyl and substituted
phenyl (8a and 8i) seem to be more effective than the
heterocyclic such moieties, except for 8s, the case in which the
4-Et instead of 4-Me leads to 12.8 times better activity of 8s
compared to pritelivir 8b (the two compounds differ only by
one CH2 group).
(III) The mitochondrial isoform hCA VA was also effectively
inhibited by most sulfonamides reported here, which showed KI
values ranging between 29.0 and 816 nM (Table 1). It should
be mentioned that hCA VA (and probably also the second
mitochondrial isoform hCA VB) are drug targets for antiobesity
agents.13 The only compound in clinical use for treating obesity
based on CAIs is topiramate, an antiepileptic for which this
second use was approved recently.13 Several sulfonamides
reported here, such as 8a, 8e, 8f, 8g, 8j, 8l, 8n, 8o, 8s, and 8t
showed better or comparable hCA VA inhibitory activity
compared to AAZ, with KI values ranging between 29.0 and
64.8 nM, being thus of considerable interest as antiobesity drug
candidates. Pritelivir and some of its congeners (8b−d, 8k)
showed weaker hCA VA inhibitory activity, with KI values
ranging between 354 and 816 nM (Table 1). SAR is more
complicated for the inhibition of this isoform, and it is
interesting to note that the most effective inhibitor was 8g
which incorporates a bulky R2 moiety, which was detrimental
Scheme 1. Synthesis of Sulfonamides 4a−h and 6
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to inhibition of isoforms hCA I and II. Other structural aspects
which lead to effective inhibition (e.g., the nature of the Het
and R1 moietiess from inhibitors 8) are similar to what
discussed above for their inhibition of hCA I and II.
(IV) The second mitochondrial isoform, hCA VB, was more
sensitive to inhibition with sulfonamides 8 compared to hCA
VA, showing KI values in the range of 23.8−441 nM. Many of
these sulfonamides were better or comparable hCA VB
inhibitors compared to AAZ, among which are 8a, 8e−g, 8j,
8l, 8o−s (KI values ranging between 23.8 and 58.2 nM).
Pritelivir 8b and its congeners 8c and 8k were the least effective
hCA VB inhibitors with inhibition constants of 251−441 nM
(Table 1).
(V) The tumor associated isoform hCA IX, a validated
antitumor drug target4,14 was effectively inhibited by
sulfonamides 8, with KI values ranging between 0.9 and 464
nM (Table 1). Only two compounds (8c and 8d) showed KI >
100 nM, whereas the remaining ones were highly effective hCA
IX inhibitors (pritelivir is one of the least effective in the group
of good inhibitors, with a KI of 81.0 nM; see Table 1). Again
the most important structural feature influencing activity is the
nature of the Het moiety at the terminal part of the tail, with
pyridyl (as sulfate, thus probably pyridinium) and N-
methylpyridinium (in 8c and 8d) leading to the least effective
inhibitors. The best substitution patterns in this part of the
molecule include the Ph (8a, 8h) and 3-fluorophenyl (8j)
moieties. Again primary and secondary sulfonamides showed
similar inhibitory properties, and the nature of the group in
position 4 of the thiazole ring was not very influential for the
inhibitory activity (Table 1).
(VI) Powerful inhibitory activity was registered also against
hCA XII, a second transmembrane isoform investigated here
(target for antiglaucoma and anticancer agents)4,14,15 with
sulfonamides 8 showing KI values ranging between 3.1 and 77.2
nM. Pritelivir 8b was the least effective hCA XII inhibitor in the
series, but several of its congeners (8a, 8h, 8j, 8l) have a KI of
3.1−5.5 nM, being highly effective inhibitors of this isoform.
SAR is similar to what was discussed above for hCA IX
inhibition, but it is interesting to note that the most effective
hCA XII inhibitor possesses the cyclopropyl moiety as R2 group
(Table 1 and Scheme 2).
Since mammalian blood is very rich in CAs (mainly isoforms
I and II),4b we also investigated the inhibition of whole blood
Scheme 2. Synthesis of Sulfonamides 8a−ta
aReagents: (i) H2SO4 2% aq; (ii) 1.25 M HCl/MeOH.
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CAs from three species, mouse, rat, and human with the
antiviral drug pritelivir (Table 2).
From data of Table 2 it can be seen that there are no
substantial differences of inhibitory power of pritelivir against
the blood CA of the different mammals included in the
investigation (all in the same order of magnitude), with the
human enzymes being the most inhibited ones (IC50 of 65.3
nM), followed by the rodent blood enzymes (see Table 2).
■ CONCLUSIONS
A series of thiazole-5-sulfonamide derivatives was prepared by
an original procedure. These compounds are congeners of the
helicase-primase inhibitor pritelivir, N-[5-(aminosulfonyl)-4-
methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]-
acetamide, currently in phase II clinical development. The
synthesized primary and secondary sulfonamides were inves-
tigated as inhibitors of six physiologically and pharmacologically
relevant hCA isoforms, the cytosolic isoforms I and II, the
mitochondrial ones hCA VA and VB, and the transmembrane,
tumor associated hCA IX and XII. Low nanomolar inhibitors
were detected for all of them, with a very interesting and well-
defined structure−activity relationship, typical for all these
different isoforms. As many CAs are involved in serious
pathologies, among which are cancer, obesity, epilepsy,
glaucoma, etc., sulfonamide inhibitors such as those reported
here may be of interest as drug candidates for all these
pathologies. Furthermore, we could confirm that pritelivir itself
is an effective inhibitor of some CA isoforms in vitro, whereas
our IC50 values were reproducibly lower than those previously
reported (Kleymann 2002). However, there are considerable
differences between the test system that was used by Kleymann
et al. and our assay leading to this discrepancy, first of all by
monitoring the dehydratase but not the hydratase enzymatic
reaction and second because of our automated (stopped-flow)
versus manual measurements.
Since pritelivir is in phase II clinical development, a variety of
in vivo data and data from treatment in humans are available. In
animal studies only the development of urinary bladder
hyperplasia in rats has been attributed to the CA inhibitory
effect of pritelivir so far.2 This proliferation of the transitional
cells is a transient, rodent-specific effect of CA inhibition which
is well-known and generally considered as not relevant for
humans. Neither adverse findings or beneficial pharmacological
effects that could be related to CA inhibition in humans have
been reported for healthy subjects or patients treated with
pritelivir as of today. However, these studies were not designed
to show effects on diseases or conditions targeted by CA
inhibitors such as cancer or obesity.
Finally, we could show that pritelivir interacts with whole
blood enzymes from several mammalian species, which may be
a favorable pharmacokinetic feature of a drug which can be
transported throughout the body bound to blood enzymes such
as CA I and II. In fact, pritelivir has a long half-life in the body
of up to 80 h allowing even once weekly dosing for suppression
of genital herpes.3
In summary, by investigating a series of primary and
secondary sulfonamides, we could identify several compounds
with one-digit nanomolar or even subnanomolar activity on
certain CA isoenzymes. A potential use of these potent
inhibitors for CA associated conditions and diseases remains to
be investigated.
■ EXPERIMENTAL PROTOCOLS
Chemistry. General. Anhydrous solvents and all reagents were
purchased from Sigma-Aldrich, Alfa Aesar, and TCI. All reactions
involving air- or moisture-sensitive compounds were performed under
a nitrogen atmosphere using dried glassware and syringes techniques
to transfer solutions. Nuclear magnetic resonance (1H NMR, 13C
NMR, 19F NMR) spectra were recorded using a Bruker Advance III
400 MHz spectrometer in DMSO-d6. Chemical shifts are reported in
parts per million (ppm), and the coupling constants (J) are expressed
in hertz (Hz). Splitting patterns are designated as follows: s, singlet; d,
doublet; t, triplet; q, quartet; m, multiplet; brs, broad singlet; dd,
doublet of doublets. The assignment of exchangeable protons (OH
and NH) was confirmed by the addition of D2O. Analytical thin-layer
chromatography (TLC) was carried out on Merck silica gel F-254
plates. Flash chromatography purifications were performed on Merck
silica gel 60 (230−400 mesh ASTM) as the stationary phase, and ethyl
acetate and n-hexane were used as eluents. Melting points (mp) were
measured in open capillary tubes with a Gallenkamp MPD350.BM3.5
apparatus and are uncorrected. HPLC was performed by using a
Waters 2690 separation module coupled with a photodiode array
detector (PDA Waters 996) and, as column, a Nova-Pak C18 4 μm,
3.9 mm × 150 mm (Waters), silica-based reverse phase column.
Sample was dissolved in acetonitrile 10%, and an injection volume of
45 μL was used. The mobile phase, at a flow rate of 1 mL/min, was a
Table 1. CA Inhibition Data against Isoforms Human
Carbonic Anhydrases (hCA) I, II, VA, VB, IX, and XII with
Compounds 8a−t and Acetazolamide (AAZ) as Standard, by
a Stopped-Flow CO2 Hydrase Assay
25
KI (nM)
a
compd hCA I hCA II hCA VA hCA VB hCA IX hCA XII
8a 26.9 0.9 67.6 55.1 0.9 4.9
8b 323.0 12.8 474.0 389.0 81.0 77.2
8c 262.0 14.0 816.0 251.0 464.0 61.3
8d 436.0 15.6 354.0 78.0 261.0 36.7
8e 378.0 248.0 32.0 58.0 35.0 77.0
8f 29.3 203 61.7 45.6 69.1 61.5
8g 264.0 79.0 29.0 47.0 22.0 59.0
8h 55.4 74.8 61.2 67.8 1.0 3.1
8i 56.1 4.9 53.5 62.0 10.1 46.5
8j 37.0 104 58.9 49.1 0.9 5.5
8k 58.5 180 560 441 51.4 75.1
8l 47.8 32.9 37.4 56.7 21.8 4.2
8m 47.4 81.5 75.4 92.3 40.8 57.3
8n 54.1 74.3 32.8 79.4 25.6 52.8
8o 44.2 341 64.8 37.8 24.7 67.0
8p 543.0 82.0 73.0 33.0 14.0 60.0
8q 73.0 122 88.1 34.9 41.0 31.6
8r 26.6 94.5 98.1 58.2 44.5 67.6
8s 48.4 1.0 60.9 23.8 28.1 48.3
8t 64.7 10.0 51.1 66.0 42.9 43.1
AAZ 250.0 12.1 63.1 54.2 25.4 5.6
aMean from three different assays, and errors were within ±10% of the
reported values, by a stopped-flow, CO2 hydrase assay.
25
Table 2. IC50 for the Inhibition of Mouse, Rat and Human
Whole Blood with Pritelivir 8b
species IC50 (nM)
a
mouse 134
rat 115
human 65.3
aMean from three different assays, errors within ±10% of the reported
values, stopped-flow, CO2 hydrase assay.
25
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gradient of water + trifluoroacetic acid (TFA) 0.1% (A) and
acetonitrile + TFA 0.1% (B), with steps as follows: (A%:B%), 0−10
min 90:10, 10−25 min gradient to 60:40, 26:28 min isocratic 20:80,
29−35 min isocratic 90:10. TFA 0.1% in water as well in acetonitrile
was used as counterion. All compounds reported here showed more
than 96% HPLC purity. The solvents used in MS measures were
acetone, acetonitrile (Chromasolv grade), purchased from Sigma-
Aldrich (Milan, Italy), and mQ water 18 MΩ, obtained from
Millipore’s Simplicity system (Milan, Italy). The mass spectra were
obtained using a Varian 1200L triple quadrupole system (Palo Alto,
CA, USA) equipped with electrospray source (ESI) operating in both
positive and negative ions. Stock solutions of analytes were prepared in
acetone at 1.0 mg mL−1 and stored at 4 °C. Working solutions of each
analyte were freshly prepared by diluting stock solutions in a mixture
of mQ H2O/ACN 1/1 (v/v) up to a concentration of 1.0 μg mL
−1
The mass spectra of each analyte were acquired by introducing, via
syringe pump at 10/L min−1, the working solution. Raw data were
collected and processed by Varian Workstation version 6.8 software.
Synthesis of 2-Chloro-4-methylthiazole-5-sulfonyl Chloride (2a)
and 2-Chloro-4-ethylthiazole-5-sulfonyl Chloride (2b).1b,22 2-
Chloro-4-methylthiazole (1a) or 2-chloro-4-ethylthiazole (1b) (1.0
equiv) was added dropwise to a solution of thionyl chloride (2.5
equiv) and chlorosulfonic acid (5.0 equiv). The reaction mixture was
stirred at 120 °C for 48 h, cooled down, quenched with slush, and
extracted with DCM (3 × 20 mL). The combined organic layers were
dried over Na2SO4, filtered-off, and concentrated under vacuo to give a
residue that was purified by fractional distillation (2a, 17 mbar, 85−95
°C; 2b, 0.9 mbar, 59−64 °C).
2-Chloro-4-methylthiazole-5-sulfonyl chloride (2a): m/z (ESI
positive) 231.90 [M + H]+.
2-Chloro-4-ethylthiazole-5-sulfonyl chloride (2b): m/z (ESI pos-
itive) 247.12 [M + H]+.
Experimental data are in agreement with reported data.1b,22
Synthesis of 2-Chloro-4-alkylthiazole-5-sulfonylamides 3a−e.22
2-Chloro-4-methylthiazole-5-sulfonyl chloride (2a) or 2-chloro-4-
ethylthiazole-5-sulfonyl chloride (2b) (1.0 equiv) was treated with
the proper amine (1.0 equiv) in THF and stirred until consumption of
the starting material occurred (TLC monitoring). Then the solvents
were removed under vacuo and the obtained residue was immediately
used for the next step without further purification.
2-Chloro-4-methylthiazole-5-sulfonamide 3a: m/z (ESI positive)
212.95 [M + H]+.22
2-Chloro-N,4-dimethylthiazole-5-sulfonamide 3b: m/z (ESI pos-
itive) 226.96 [M + H]+.
2-Chloro-N-(2-hydroxyethyl)-4-methylthiazole-5-sulfonamide 3c:
m/z (ESI positive) 256.97 [M + H]+.
2-Chloro-N-cyclopropyl-4-methylthiazole-5-sulfonamide 3d: m/z
(ESI positive) 252.98 [M + H]+.
2-Chloro-4-ethyl-N-methylthiazole-5-sulfonamide 3e: m/z (ESI
positive) 240.98 [M + H]+.
Synthesis of 4-Alkyl-2-(alkylamino)thiazole-5-sulfonamido De-
rivatives 4a−h.22 2-Chloro-4-alkylthiazole-5-sulfonylamides 3a−e (1.0
equiv) were dissolved in acetonitrile and treated with the appropriate
amine (3.3 equiv) at 50 °C until consumption of the starting material
(TLC monitoring). The reaction solution was cooled down to rt, and
the solvent was removed under vacuo to give a residue that was treated
with H2O. The solid formed was collected by filtration and dried under
vacuo to afford the title compounds which did not require further
purification.
4-Methyl-2-(methylamino)thiazole-5-sulfonamide (4a): mp 192
°C;22 m/z (ESI positive) 208.01 [M + H]+.
2-((2-(Dimethylamino)ethyl)amino)-4-methylthiazole-5-sulfona-
mide (4b): m/z (ESI positive) 265.07 [M + H]+.
2-(Cyclopropylamino)-4-methylthiazole-5-sulfonamide (4c): m/z
(ESI positive) 234.03 [M + H]+.
N,4-Dimethyl-2-(methylamino)thiazole-5-sulfonamide (4d): m/z
(ESI positive) 222.03 [M + H]+.
2-((2-(Dimethylamino)ethyl)amino)-N,4-dimethylthiazole-5-sulfo-
namide (4e): m/z (ESI positive) 279.09 [M + H]+.
N-Cyclopropyl-4-methyl-2-(methylamino)thiazole-5-sulfonamide
(4f): m/z (ESI positive) 248.04 [M + H]+.
N-(2-Hydroxyethyl)-4-methyl-2-(methylamino)thiazole-5-sulfona-
mide (4g): m/z (ESI positive) 252.04 [M + H]+.
4-Ethyl-2-(methylamino)thiazole-5-sulfonamide (4h): m/z (ESI
positive) 222.03 [M + H]+.
Synthesis of 4-(Hydroxymethyl)-2-(methylamino)thiazole-5-sul-
fonamide (6). 4-Methyl-2-(methylamino)thiazole-5-sulfonamide (4a)
(1.0 equiv) was dissolved in MeOAc and treated with NBS (1.0 equiv)
and AIBN cat. at rt for 3 h. Then the solvents were removed under
vacuo and the residue was purified by silica gel column
chromatography, eluting with 30% ethyl acetate in n-hexane followed
by trituration in DCM to afford 4-(bromomethyl)-2-(methylamino)-
thiazole-5-sulfonamide (5) which was treated with a 1/1 solution of
H2O/1,4-dioxane at 100 °C. The solvents were removed in vacuo and
the obtained residue was triturated from DCM to afford the title
compound (6) in 98% yield: δH (400 MHz, DMSO-d6) 3.10 (3H, d, J
6.2, N-CH3), 4.72 (2H, d, J 6.4, CH2), 4.80 (2H, t, J 6.4, exchange with
D2O, OH), 7.20 (1H, brs, exchange with D2O, NH), 7.56 (2H, s,
exchange with D2O, SO2NH2); δC (100 MHz, DMSO-d6) 29.8, 58.6,
110.1, 148.2, 165.0; m/z (ESI positive) 224.01 [M + H]+.
Synthesis of N-Alkyl-N-(4-alkyl-5-sulfamoylthiazol-2-yl)-2-(4-
aryl-2-ylphenyl)acetamides 8a−t.1b The proper acid 7a−i (1.0
equiv) was dissolved in dry DMF an treated with 1-hydroxy-1H-
benzotriazole (HOBT; 1.0 equiv) for 10 min at rt, followed by
addition of the corresponding 4-alkyl-2-(alkylamino)thiazole-5-sulfo-
namido derivatives 4a−h, 6 (1.1 equiv), and N-(3-dimethylamino-
propyl)-N′-ethylcarbodiimide hydrochloride (EDCI·HCl; 1.1 equiv).
The reaction mixture was stirred at rt under a nitrogen atmosphere
until consumption of the starting material. Then the solvent was
removed under vacuo and the obtained residue was triturated from
DCM or H2O to afford the titled compounds in the pure form.
2-([1,1′-Biphenyl]-4-yl)-N-methyl-N-(4-methyl-5-sulfamoylthiazol-
2-yl)acetamide (8a) was obtained according to the previously reported
general procedure, by using 4a and 7a, in 83% yield: mp 193 °C; δH
(400 MHz, DMSO-d6) 2.48 (3H, s, CH3), 3.71 (3H, s, N-CH3), 4.23
(2H, s, CH2), 7.38 (1H, m, Ar-H), 7.48 (2H, d, J 8.4, Ar-H), 7.50 (2H,
d, J 8.4, Ar-H), 7.65 (2H, s, exchange with D2O, SO2NH2), 7.80 (2H,
d, J 8.4, Ar-H); δC (100 MHz, DMSO-d6) 16.5, 35.0, 42.3, 127.5,
128.0, 128.5, 129.0, 130.6, 134.2, 139.8, 140.1, 148.0, 148.1, 160.2,
171.0; m/z (ESI positive) 402.09 [M + H]+.
N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-pyridin-2-
ylphenyl)acetamide (8b) was obtained according to the previously
reported general procedure, by using 4a and 7b, in 74% yield: mp 190
°C; δH (400 MHz, DMSO-d6) 2.48 (3H, s, CH3), 3.71 (3H, s, N-
CH3), 4.23 (2H, s, CH2), 7.32 (1H, m, Ar-H), 7.63 (2H, d, J 8.4, Ar-
H), 7.67 (2H, s, exchange with D2O, SO2NH2), 7.85 (2H, appt, J 8.8,
Ar-H), 8.00 (1H, d, J 8.8, Ar-H), 8.10 (2H, d, J 8.4, Ar-H), 8.66 (1H, d,
J 8.8, Ar-H); δC (100 MHz, DMSO-d6) 16.6, 34.7, 42.0, 120.6, 123.0,
127.0, 128.7, 130.6, 135.4, 137.7, 137.8, 148.6, 150.0, 156.2, 158.9,
172.3; m/z (ESI positive) 403.08 [M + H]+.
Bis [N-Methyl-N-(4-methyl-5-sulfamoyl-thiazol-2-yl)-2-(4-pyridin-
2-yl-phenyl)-acetamide] sulfate salt (8c) was obtained by the following
method.
N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-pyridin-2-
ylphenyl)acetamide (8b) (1.0 equiv) was treated at 0 °C with a
2% w/w aqueous solution of H2SO4 (0.6 equiv). The
precipitate formed was collected by filtration, washed with
H2O, and dried under vacuo to afford 8c in 90% yield. δH (400
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MHz, DMSO-d6) 2.48 (3H, s, CH3), 3.71 (3H, s, N-CH3), 4.23
(2H, s, CH2), 7.32 (1H, m, Ar-H), 7.63 (2H, d, J 8.4, Ar-H),
7.67 (2H, s, exchange with D2O, SO2NH2), 7.85 (2H, appt, J
8.8, Ar-H), 7.99 (1H, d, J 8.8, Ar-H), 8.14 (2H, d, J 8.4, Ar-H),
8.68 (1H, d, J 8.8, Ar-H); δC (100 MHz, DMSO-d6) 16.6, 34.7,
42.0, 120.6, 123.0, 127.0, 128.7, 130.6, 135.4, 137.7, 137.8,
148.6, 150.0, 156.2, 158.9, 172.3; m/z (ESI positive) 403.08 [M
− HSO4−]+.
1-Methyl-2-(4-(2-(methyl(4-methyl-5-sulfamoylthiazol-2-yl)-
amino)-2-oxoethyl)phenyl)pyridin-1-ium acetate salt (8d) was ob-
tained according to the previously reported general procedure, by
using 4a and 7c, in 89% yield: δH (400 MHz, DMSO-d6) 2.15 (3H, s,
CH3-CO2), 2.25 (3H, s, CH3), 3.52 (3H, s, N-CH3), 4.14 (3H, s, N
+-
CH3), 4.26 (2H, s, CH2), 7.63 (2H, d, J 8.4, Ar-H), 7.59 (2H, s,
exchange with D2O, SO2NH2), 7.80 (2H, d, J 8.4, Ar-H), 7.82 (1H,
appt, J 8.8, Ar-H), 8.38 (1H, appt, J 8.8, Ar-H), 8.52 (1H, d, J 8.8, Ar-
H), 9.30 (1H, d, J 8.8, Ar-H); δC (100 MHz, DMSO-d6) 17.0, 22.0,
23.1, 33.9, 39.8, 42.0, 121.0, 123.0, 125.1, 128.7, 130.0, 132.1, 136.5,
143.2, 146.0, 148.8, 150.4, 159.0, 171.9, 172.3, 175.0; m/z (ESI
positive) 417.10 [M − CH3CO2−]+.
N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-pyrazol-1-
ylphenyl)acetamide (8e) was obtained according to the previously
reported general procedure, by using 4a and 7e, in 60% yield: δH (400
MHz, DMSO-d6) 2.46 (3H, s, CH3), 3.69 (3H, s, N-CH3), 4.20 (2H, s,
CH2), 6.42 (1H, s, Ar-H), 7.42 (2H, d, J 8.4, Ar-H), 7.48 (1H, s, Ar-
H), 7.58 (2H, d, J 8.4, Ar-H), 7.63 (2H, s, exchange with D2O,
SO2NH2), 8.00 (1H, s; Ar-H); δC (100 MHz, DMSO-d6) 15.8, 32.0,
42.0, 110.1, 112.4, 125.7, 126.8, 130.2, 131.1, 138.6, 141.0, 147.9,
159.0, 170.1; m/z (ESI positive) 391.08 [M + H]+.
N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyrazin-2-yl)-
phenyl)acetamide (8f) was obtained according to the previously
reported general procedure, by using 4a and 7d, in 63% yield: mp 220
°C; δH (400 MHz, DMSO-d6) 2.30 (3H, s, CH3), 3.7 (3H, s, N-CH3),
4.08 (2H, s, CH2), 7.53 (2H, s, exchange with D2O, SO2NH2), 7.65
(2H, d, J 8.4, Ar-H), 8.10 (2H, d, J 8.4, Ar-H), 8.76 (1H, s, Ar-H), 8.80
(1H, d, J 8.8, Ar-H), 8.82 (1H, d, J 8.8, Ar-H); δC (100 MHz, DMSO-
d6) 15.4, 32.0, 41.9, 111.0, 126.5, 130.3, 135.8, 142.4, 143.4, 144.8,
148.0, 153.2, 160.4, 172.3; m/z (ESI positive) 404.08 [M + H]+.
2-([1,1′-Biphenyl]-4-yl)-N-(2-(dimethylamino)ethyl)-N-(4-methyl-
5-sulfamoylthiazol-2-yl)acetamide (8g) was obtained according to the
previously reported general procedure, by using 4b and 7a, in 72%
yield: δH (400 MHz, DMSO-d6) 2.30 (3H, s, CH3), 2.35 (6H, s, 2 ×
N-CH3), 2.71 (2H, t, J 6.4 CH2-CH2-N(CH3)2), 3.64 (2H, t, J 6.4
CH2-CH2-N(CH3)2), 3.92 (2H, s, CH2), 7.40 (1H, m, Ar-H), 7.50
(2H, d, J 8.4, Ar-H), 7.54 (2H, d, J 8.4, Ar-H), 7.68 (2H, s, exchange
with D2O, SO2NH2), 7.79 (2H, d, J 8.4, Ar-H); δC (100 MHz, DMSO-
d6) 16.0, 42.4, 48.0, 48.1, 60.2, 110.4, 128.0, 128.5, 129.0, 130.6, 134.2,
139.8, 140.1, 148.0, 148.1, 160.2, 172.0; m/z (ESI positive) 459.14 [M
+ H]+.
2-([1,1′-Biphenyl]-4-yl)-N-cyclopropyl-N-(4-methyl-5-sulfamoyl-
thiazol-2-yl)acetamide (8h) was obtained according to the previously
reported general procedure, by using 4c and 7a, in 82% yield: mp 164
°C; δH (400 MHz, DMSO-d6) 1.06 (2H, m), 1.32 (2H, m), 2.16 (3H,
s, CH3) 3.98 (2H, s, CH2), 4.18 (1H, m), 7.36 (2H, d, J 8.4; Ar-H),
7.39 (1H, appt, J 8.4, Ar-H), 7.49 (2H, d, J 8.4, Ar-H), 7.53 (2H, s,
exchange with D2O, SO2NH2), 7.70 (2H, d, J 8.4, Ar-H), 7.78 (2H, d, J
8.4; Ar-H); δC (100 MHz, DMSO-d6) 10.4, 15.9, 35.0, 38.4, 110.1,
127.8, 128.0, 128.3, 129.1, 130.4, 135.0, 139.9, 141.1, 148.0, 162.3,
169.4; m/z (ESI positive) 428.10 [M + H]+.
2-(2′-Fluoro-[1,1′-biphenyl]-4-yl)-N-methyl-N-(4-methyl-5-sulfa-
moylthiazol-2-yl)acetamide (8i) was obtained according to the
previously reported general procedure, by using 4a and 7f, in 94%
yield: mp 209 °C; δH (400 MHz, DMSO-d6) 2.20 (3H, s, CH3) 3.78
(s, N-CH3), 4.12 (2H, s, CH2), 7.27 (1H, appt, J 8.7, Ar-H), 7.38 (2H,
d, J 8.4; Ar-H), 7.49 (1H, m, Ar-H), 7.53 (2H, s, exchange with D2O,
SO2NH2), 7.63 (2H, d, J 8.4, Ar-H), 7.69 (1H, appt, J 8.6, Ar-H), 7.75
(2H, d, J 8.6; Ar-H); δC (100 MHz, DMSO-d6) 16.2, 32.0, 39.2, 110.4,
115.8 (d, JC−F 23.5), 125.0, 128.2, 129.1, 129.3 (d, JC−F 23.5), 130.2,
130.9, 134.6, 135.0, 148.0, 158.9, (d, JC−F 247) 159.1, 171.3; m/z (ESI
positive) 420.08 [M + H]+.
2-(3′-Fluoro-[1,1′-biphenyl]-4-yl)-N-methyl-N-(4-methyl-5-
sulfamoylthiazol-2-yl)acetamide (8j) was obtained according to the
previously reported general procedure, by using 4a and 7g, in 84%
yield; mp 148 °C; δH (400 MHz, DMSO-d6) 2.20 (3H, s, CH3) 3.78
(s, N-CH3), 4.12 (2H, s, CH2), 7.21 (1H, m, Ar-H), 7.28 (1H, d, J 8.4;
Ar-H), 7.38 (1H, d, J 8.4; Ar-H), 7.53 (2H, s, exchange with D2O,
SO2NH2), 7.54 (2H, m, Ar-H), 7.65 (2H, d, J 8.4, Ar-H); δC (100
MHz, DMSO-d6) 16.0, 32.4, 40.1, 114.1 (d, JC−F 24.0), 116.1 (d, JC−F
24.0), 123.6, 127.8, 128.1, 130.2, 130.9, 134.5, 139.9, 141.2, 148.0,
159.1, 162.1 (d, JC−F 247), 171.0; m/z (ESI positive) 420.08 [M +
H]+.
2-(2′,5′-Difluoro-[1,1′-biphenyl]-4-yl)-N-methyl-N-(4-methyl-5-
sulfamoylthiazol-2-yl)acetamide (8k) was obtained according to the
previously reported general procedure, by using 4a and 7h, in 80%
yield: mp 188 °C; δH (400 MHz, DMSO-d6) 2.19 (3H, s, CH3) 3.80
(s, N-CH3), 4.12 (2H, s, CH2), 7.23 (1H, m, Ar-H), 7.36 (1H, m; Ar-
H), 7.37 (2H, d, J 8.4; Ar-H), 7.50 (1H, m; Ar-H), 7.52 (2H, s,
exchange with D2O, SO2NH2), 7.64 (2H, d, J 8.4, Ar-H); δC (100
MHz, DMSO-d6) 16.0, 32.0, 40.3, 110.1, 116.0, 116.1 (d, JC−F 24.0),
118.0 (d, JC−F 24.0), 128.2, 130.0, 132.9, 134.4, 135.4, 148.0, 154.5,
157.4 (d, JC−F 247), 158.0 (d, JC−F 247), 159.1, 171.3; m/z (ESI
positive) 438.07 [M + H]+.
2-(3′-Fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-N-methyl-N-(4-
methyl-5-sulfamoylthiazol-2-yl)acetamide (8l) was obtained according
to the previously reported general procedure, by using 4a and 7i, in
65% yield; δH (400 MHz, DMSO-d6) 2.20 (3H, s, CH3), 3.78 (s, N-
CH3), 3.80 (3H, s, O-CH3), 4.11 (2H, s, CH2), 7.21 (1H, m, Ar-H),
7.30 (1H, m; Ar-H), 7.38 (2H, d, J 8.4; Ar-H), 7.52 (2H, s, exchange
with D2O, SO2NH2), 7.63 (2H, d, J 8.4, Ar-H), 7.74 (1H, m, Ar-H); δC
(100 MHz, DMSO-d6) 16.0, 32.1, 40.2, 58.1, 110.1, 115.4 (d, JC−F
24.0), 119.3, 126.2, 127.3, 128.2, 130.1, 134.6, 136.4, 148.0 (d, JC−F
24), 148.1, 152.4 (d, JC−F 247), 156.0, 171.4; m/z (ESI positive)
450.09 [M + H]+.
2 -([1 ,1 ′ -B ipheny l] -4 -y l ) -N -methy l -N - (4 -methy l -5 -(N -
methylsulfamoyl)thiazol-2-yl)acetamide (8m) was obtained according
to the previously reported general procedure, by using 4d and 7a, in
93% yield: mp 177 °C; δH (400 MHz, DMSO-d6) 2.21 (3H, s, CH3),
2.50 (3H, s, SO2NH-CH3), 3.80 (s, N-CH3), 4.12 (2H, s, CH2), 7.41
(1H, appt, J 6.84, Ar-H), 7.38 (2H, d, J 8.4; Ar-H), 7.49 (2H, d, J 8.4;
Ar-H), 7.63 (2H, d, J 8.4, Ar-H), 7.72 (2H, d, J 8.4, Ar-H), 7.75 (1H, s,
exchange with D2O, SO2NH-); δC (100 MHz, DMSO-d6) 16.4, 30.1,
32.0, 40.2, 110.4, 127.4, 127.6, 128.2, 129.0, 129.8, 134.5, 139.6, 140.1,
148.0, 159.1, 172.3; m/z (ESI positive) 416.10 [M + H]+.
2-(2′-Fluoro-[1,1′-biphenyl]-4-yl)-N-methyl-N-(4-methyl-5-(N-
methylsulfamoyl)thiazol-2-yl)acetamide (8n) was obtained according
to the previously reported general procedure, by using 4d and 7f, in
87% yield: mp 182 °C; δH (400 MHz, DMSO-d6) 2.20 (3H, s, CH3),
2.50 (3H, s, SO2NH-CH3), 3.78 (s, N-CH3), 4.12 (2H, s, CH2), 7.27
(1H, appt, J 8.7, Ar-H), 7.38 (2H, d, J 8.4; Ar-H), 7.49 (1H, m, Ar-H),
7.63 (2H, d, J 8.4, Ar-H), 7.69 (1H, appt, J 8.6, Ar-H), 7.75 (2H, d, J
8.6; Ar-H), 7.76 (1H, s, exchange with D2O, SO2NH-); δC (100 MHz,
DMSO-d6) 16.2, 30.4, 32.0, 39.2, 110.4, 115.8 (d, JC−F 23.5), 125.0,
128.2, 129.1, 129.3 (d, JC−F 23.5), 130.2, 130.9, 134.6, 135.0, 148.0,
158.9, (d, JC−F 247) 159.1, 171.3; m/z (ESI positive) 434.09 [M +
H]+.
N-Methyl-N-(4-methyl-5-(N-methylsulfamoyl)thiazol-2-yl)-2-(4-
(pyridin-2-yl)phenyl)acetamide hydrochloride salt (8o) was obtained
according to the following procedure.
N-Methyl-N-(4-methyl-5-(N-methylsulfamoyl)thiazol-2-yl)-2-
(4-(pyridin-2-yl)phenyl)acetamide (8o′) was treated with a
commercially available 1.25 M hydrochloric acid solution in
methanol. The precipitate formed was collected by filtration
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and dried under vacuo to afford the compound 8o in 98% yield:
mp 240 °C; δH (400 MHz, DMSO-d6) 2.20 (3H, s, CH3), 2.50
(3H, s, SO2NH-CH3), 3.78 (s, N-CH3), 4.15 (2H, s, CH2), 7.32
(1H, m, Ar-H), 7.63 (2H, d, J 8.4, Ar-H), 7.74 (1H, s, exchange
with D2O, SO2NH-), 7.85 (2H, appt, J 8.8, Ar-H), 7.99 (1H, d,
J 8.8, Ar-H), 8.14 (2H, d, J 8.4, Ar-H), 8.68 (1H, d, J 8.8, Ar-H);
δC (100 MHz, DMSO-d6) 16.6, 30.2, 34.7, 42.0, 120.6, 123.0,
127.0, 128.7, 130.6, 135.4, 137.7, 137.8, 148.6, 150.0, 156.2,
158.9, 172.2; m/z (ESI positive) 432.12 [MH − Cl−]+.
2-([1,1′-Biphenyl]-4-yl)-N-(2-(dimethylamino)ethyl)-N-(4-methyl-
5-(N-methylsulfamoyl)thiazol-2-yl)acetamide (8p) was obtained
according to the previously reported general procedure, by using 4e
and 7a, in 81% yield: δH (400 MHz, DMSO-d6) 2.21 (3H, s, CH3),
2.35 (6H, s, 2 × N-CH3), 2.50 (3H, s, SO2NH-CH3), 2.71 (2H, t, J 6.4
CH2-CH2-N(CH3)2), 3.64 (2H, t, J 6.4 CH2-CH2-N(CH3)2), 3.80 (s,
N-CH3), 4.13 (2H, s, CH2), 7.41 (1H, appt, J 6.84, Ar-H), 7.38 (2H, d,
J 8.4; Ar-H), 7.49 (2H, d, J 8.4; Ar-H), 7.63 (2H, d, J 8.4, Ar-H), 7.72
(2H, d, J 8.4, Ar-H), 7.74 (1H, s, exchange with D2O, SO2NH-); δC
(100 MHz, DMSO-d6) 16.4, 32.1, 42.4, 48.0, 48.1, 110.3, 127.6, 127.8,
128.3, 129.0, 130.0, 134.5, 139.8, 141.0, 148.0, 159.0, 172.2; m/z (ESI
positive) 473.16 [M + H]+.
N-(5-(N-Cyclopropylsulfamoyl)-4-methylthiazol-2-yl)-N-methyl-2-
(4-(pyridin-2-yl)phenyl)acetamide (8q) was obtained according to the
previously reported general procedure, by using 4f and 7b, in 77%
yield: δH (400 MHz, DMSO-d6) 1.06 (2H, m), 1.32 (2H, m), 2.48
(3H, s, CH3), 3.71 (3H, s, N-CH3), 4.20 (2H, s, CH2), 4.22 (1H, m),
7.32 (1H, m, Ar-H), 7.63 (2H, d, J 8.4, Ar-H), 7.74 (1H, s, exchange
with D2O, SO2NH-), 7.85 (2H, appt, J 8.8, Ar-H), 8.00 (1H, d, J 8.8,
Ar-H), 8.10 (2H, d, J 8.4, Ar-H), 8.66 (1H, d, J 8.8, Ar-H); δC (100
MHz, DMSO-d6) 14.2, 16.7, 20.0, 31.2, 38.0, 110.2, 121.0, 123.2,
126.4, 130.1, 134.2, 137.2, 138.0, 148.4, 150.0, 155.7, 159.0, 172.0; m/z
(ESI positive) 443.11 [M + H]+.
2-([1,1′-Biphenyl]-4-yl)-N-(5-(N-(2-hydroxyethyl)sulfamoyl)-4-
methylthiazol-2-yl)-N-methylacetamide (8r) was obtained according
to the previously reported general procedure, by using 4g and 7a, in
88% yield: mp 170 °C; δH (400 MHz, DMSO-d6) 2.21 (3H, s, CH3),
3.00 (2H, dd, J 6.4, 6.6, SO2NH-CH2-), 3.43 (2H, m, -CH2-OH), 3.82
(s, N-CH3), 4.10 (2H, s, CH2), 4.45 (1H, t, J 6.4, exchange with D2O,
OH), 7.38 (2H, d, J 8.4; Ar-H), 7.41 (1H, appt, J 6.84, Ar-H), 7.49
(2H, d, J 8.4; Ar-H), 7.63 (2H, d, J 8.4, Ar-H), 7.72 (2H, d, J 8.4, Ar-
H), 7.73 (1H, s, exchange with D2O, SO2NH-), 7.75 (2H, d, J 8.4, Ar-
H); δC (100 MHz, DMSO-d6) 16.2, 30.1, 38.4, 45.6, 59.9, 110.2, 127.6,
128.0, 128.2, 129.0, 130.0, 134.5, 140.0, 140.9, 148.1, 159.8, 172.2; m/z
(ESI positive) 446.11 [M + H]+.
N-(4-Ethyl-5-sulfamoylthiazol-2-yl)-N-methyl-2-(4-(pyridin-2-yl)-
phenyl)acetamide (8s) was obtained according to the previously
reported general procedure, by using 4h and 7b, in 82% yield: δH (400
MHz, DMSO-d6) 1.35 (3H, d, J 6.4, CH2-CH3), 3.00 (2H, q, J 6.4,
CH2-CH3), 3.71 (3H, s, N-CH3), 4.22 (2H, s, CH2), 7.32 (1H, m, Ar-
H), 7.63 (2H, d, J 8.4, Ar-H), 7.66 (2H, s, exchange with D2O,
SO2NH2), 7.85 (2H, appt, J 8.8, Ar-H), 8.00 (1H, d, J 8.8, Ar-H), 8.10
(2H, d, J 8.4, Ar-H), 8.66 (1H, d, J 8.8, Ar-H); δC (100 MHz, DMSO-
d6) 14.2, 19.9, 34.7, 42.0, 120.6, 123.0, 127.0, 128.7, 130.6, 135.4,
137.7, 137.8, 148.6, 150.0, 156.2, 159.1, 172.0; m/z (ESI positive)
417.10 [M + H]+.
N-(4-(Hydroxymethyl)-5-sulfamoylthiazol-2-yl)-N-methyl-2-(4-
(pyridin-2-yl)phenyl)acetamide (8t) was obtained according to the
previously reported general procedure, by using 6 and 7b, in 64%
yield: δH (400 MHz, DMSO-d6) 3.72 (3H, s, N-CH3), 4.20 (2H, s,
CH2), 4.60 (2H, d, J 6.2, CH2OH), 4.78 (1H, t, J 6.2, OH), 7.32 (1H,
m, Ar-H), 7.63 (2H, d, J 8.4, Ar-H), 7.66 (2H, s, exchange with D2O,
SO2NH2), 7.85 (2H, appt, J 8.8, Ar-H), 8.00 (1H, d, J 8.8, Ar-H), 8.10
(2H, d, J 8.4, Ar-H), 8.66 (1H, d, J 8.8, Ar-H); δC (100 MHz, DMSO-
d6) 14.2, 19.9, 34.7, 42.0, 120.6, 123.0, 127.0, 128.7, 130.6, 135.4,
137.7, 137.8, 148.6, 150.0, 156.2, 159.1, 172.0; m/z (ESI positive)
417.10 [M + H]+.
CA Inhibition. An Applied Photophysics stopped-flow instrument
has been used for assaying the CA catalyzed CO2 hydration activity.
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Phenol red (at a concentration of 0.2 mM) has been used as indicator,
working at the absorbance maximum of 557 nm, with 20 mM Hepes
(pH 7.5) as buffer and 20 mM Na2SO4 (for maintaining constant the
ionic strength), following the initial rates of the CA-catalyzed CO2
hydration reaction for a period of 10−100 s. The CO2 concentrations
ranged from 1.7 to 17 mM for the determination of the kinetic
parameters and inhibition constants. For each inhibitor at least six
traces of the initial 5−10% of the reaction have been used for
determining the initial velocity. The uncatalyzed rates were
determined in the same manner and subtracted from the total
observed rates. Stock solutions of inhibitor (0.1 mM) were prepared in
distilled−deionized water, and dilutions up to 0.01 nM were done
thereafter with the assay buffer. Inhibitor and enzyme solutions were
preincubated together for 15 min at room temperature prior to assay,
in order to allow for the formation of the E−I complex. The inhibition
constants were obtained by nonlinear least-squares methods using
PRISM 3 and the Cheng−Prusoff equation, as reported earlier,26−29
and represent the mean from at least three different determinations.
All CA isofoms were recombinant ones obtained in-house as reported
earlier,26−29 and their concentrations in the assay system were in the
range of 7.1−12.3 nM.
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